Risk factors for colonisation or infection by Acinetobacter baumannii resistant to carbapenems in adult patients hospitalised in Intensive Care Units in Bogota, Colombia;Factores de riesgo para infección o colonización por Acinetobacter baumannii resistente a carbapenémicos en pacientes adultos hospitalizados en Unidades de Cuidado Intensivo, Bogotá, Colombia

Infectio

Volumn 20, Issue 4, 2016, Pages 238-249

  Saavedra Trujillo, Carlos Humberto ^a,b   Arias León, Gerson ^a   Gualtero Trujillo, Sandra Milena ^a   Leal, Aura Lucía ^a,b   Saavedra Rojas, Sandra Yamile ^a   Murcia, Martha Isabel ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Grupo para el Control de la Resistencia Bacteriana en Bogotá   (Colombia)

Author keywords

Acinetobacter baumannii; Carbapenems; Intensive care units Gracias; Intensive therapy; Multidrug resistance; Risk factor's

Indexed keywords

CARBAPENEM DERIVATIVE; POLYMYXIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CASE CONTROL STUDY; COLOMBIA; CONTROLLED STUDY; GENETIC IDENTIFICATION; GENOTYPE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; SENSITIVITY ANALYSIS;

EID: 85006234917     PISSN: 01239392     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.infect.2015.11.003     Document Type: Article

References (36)

1. 1 Lemos, E.V., de la Hoz, F.P., Einarson, T.R., McGhan, W.F., Quevedo, E., Castañeda, C., et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: Systematic review and meta-analysis. Clin Microbiol Infect. 20:5 (2014), 416–423, 10.1111/1469-0691.12363.
2. 2 Joly-Guillou, M.L., Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 11:11 (2005), 868–873 [consultado 17 Sep 2013] Disponible en: doi: http://doi.org/dbc2q6.
3. 3 Gordon, N.C., Wareham, D.W., Multidrug-resistant Acinetobacter baumannii: Mechanisms of virulence and resistance. Int J Antimicrob Agents. 35:3 (2010), 219–226 [consultado 17 Sep 2013] Disponible en: doi: http://doi.org/ds7b7q.
4. 4 Falagas, M.E., Rafailidis, P.I., Attributable mortality of Acinetobacter baumannii: No longer a controversial issue. Critical Care. 11:3 (2007), 134–136, 10.1186/cc5911.
5. 5 Rajamohan, G., Srinivasan, V.B., Gebreyes, W.A., Molecular and functional characterization of a novel efflux pump, AmvA, mediating antimicrobial and disinfectant resistance in Acinetobacter baumannii. J Antimicrob Chemother 65:9 (2010), 1919–1925, 10.1093/jac/dkq195.
6. 6 GREBO. Boletín informativo. Número 1 [consultado 30 Mar 2015]. Bogotá: GREBO; 2008 [consultado 22 Sep 2013]. Disponible en: http://goo.gl/mt46b7.
7. 7 Coelho, J.M., Turton, J.F., Kaufmann, M.E., Glover, J., Woodford, N., Warner, M., et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol. 44:10 (2006), 3623–3627, 10.1128/JCM. 00699-06.
8. 8 Falagas, M.E., Bliziotis, I., Siempos, I., Attributable mortality of Acinetobacter baumannii infections in critically ill patients: A systematic review of matched cohort and case-control studies. Crit Care., 10(2), 2006, R48, 10.1186/cc4869.
9. 9 Lemos, E.V., de la Hoz, F.P., Alvis, N., Einarson, T.R., Quevedo, E., Castañeda, C., et al. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia. Clin Microbiol Infect. 20:2 (2014), 174–180, 10.1111/1469-0691.12251.
10. 10 Foppa, I., Spiegelman, D., Power and sample size calculations for case control studies of gene-environment interactions with a polytomous exposure variable. Am J Epidemiol 146:7 (1997), 596–604 [consultado 16 Sep 2013] Disponible en: http://goo.gl/vivVZr.
11. 11 Garner, J.S., Jarvis, W.R., Emori, T.G., Horan, T.C., Hughes, J.M., CDC definitions for nosocomial infections. Am J Infect Control. 16:3 (1988), 128–140 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/d69qz9.
12. 12 Woodford, N., Ellington, M., Coelho, J.M., Turton, J., Ward, M., Brown, S., et al. Multiplex PCR for genes encoding prevalent OXA carbapenemasas in Acinetobacter spp. Int J Antimicrob Agents. 27 (2006), 351–353.
13. 13 Mendes, R., Kiyota, K., Monteiro, J., Castanheira, M., Andrade, S., Gales, A., et al. Rapid detection and identification of metallo-b- lactamase-encoding genes by real-time PCR Assay and melt curve analysis. J Clin Microbiol. 45:2 (2007), 544–547 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/dcntxc.
14. 14 Seifert, H., Dolzani, L., Bressan, R., van der Reijden, T., van Strijen, B., Stefanik, D., et al. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol. 43:9 (2005), 4328–4335 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/d6sr2n.
15. 15 Marra, A., de Almeida, S., Correa, L., The effect of limit antimicrobial therapy duration on antimicrobial resistance in the critical care setting. Am J Infect Control. 37:3 (2009), 204–209 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/d7hhbz.
16. 16 Falagas, M., Kopterides, P., Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review of the literature. J Hosp Infect. 64:1 (2006), 7–115 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/fdd85v.
17. 17 Tsakiridou, E., Makris, D., Daniil, Z., Manoulakas, E., Chatzipantazi, V., Vlachos, O., et al. Acinetobacter baumannii infection in prior ICU bed occupants is an independent risk factor for subsequent cases of ventilator-associated pneumonia. Biomed Res Int., 2014, 2014, 7, 10.1155/2014/193516.
18. 18 Li, Y., Guo, Q., Wang, P., Zhu, D., Ye, X., Wu, S., et al. Clonal dissemination of extensively drug-resistant Acinetobacter baumannii producing an OXA-23 β-lactamase at a teaching hospital in Shanghai, China. J Microbiol Immunol Infect. 48:1 (2015), 101–108, 10.1016/j.jmii.2014.04.005 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/29f.
19. 19 Higgins, P.G., Dammhayn, C., Hackel, M., Seifert, H., Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother., 65(2), 2010, 1317, 10.1093/jac/dkp428.
20. 20 Woodford, N., Turton, J.F., Livermore, D.M., Multiresistant Gram-negative bacteria: The role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 35:5 (2011), 736–755 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/bdt5wj.
21. 21 Urban, C., Segal-Maurer, S., Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis. 36:10 (2003), 1268–1274, 10.1086/374847.
22. 22 Larson, E., Quiros, D., Giblin, T., Lin, S., Relationship of antimicrobial control policies and hospital and infection control characteristics to antimicrobial resistance rates. Am J Crit Care. 16:2 (2007), 110–120.
23. 23 Corbella, X., Montero, A., Pujol, M., Domiguez, M.A., Ayats, J., Argerich, M.J., et al. Emergence and rapid spread of carbapenem resistance during a large and 1 sustained hospital outbreak of multiresistant Acinetobacter baumannii. J. Clin Microbiol. 38:11 (2000), 4086–4095.
24. 24 Van den Broek, P.J., Arends, J., Bernards, A., Epidemiology of multiple Acinetobacter outbreaks in the Netherlands during the period 1999-2001. Clin Microbiol Infect. 12:9 (2006), 837–843 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/dkkn4j.
25. 25 Zarrilli, R., Casillo, R., Di Popolo, A., Tripodi, M.F., Bagattini, M., Cuccurullo, S., et al. Molecular epidemiology of a clonal outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Italy. Clin Microbiol infect. 13:5 (2007), 481–489 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/c99j7g.
26. 26 Chan, J.D., Graves, J.A., Dellit, T.H., Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 25:6 (2010), 343–348 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/cw75mg.
27. 27 Falagas, M.E., Sideri, G., Korbila, I.P., Vouloumanou, E.K., Papadatos, J.H., Kafetzis, D.A., Inhaled colistin for the treatment of tracheobronchitis and pneumonia in critically ill children without cystic fibrosis. Pediatr Pulmonol. 45:11 (2010), 1135–1140, 10.1002/ppul.21302.
28. 28 Betrosian, A.P., Frantzeskaki, F., Xanthaki, A., Douzinas, E.E., Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect. 56 (2008), 432–436, 10.1016/j.jinf.2008.04.002.
29. 29 Segal, H., Elisha, G., Use of Etest MBL strips for the detection of carbapenemases in Acinetobacter baumannii. J Antimicrob Chemother., 56(3), 2005, 598, 10.1093/jac/dki265.
30. 30 Lee, K., Lim, Y.S., Yong, D., Yum, J.H., Chong, Y., Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta- 15 lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 41 (2003), 4623–4629.
31. 31 Mugnier, P., Poirel, L., Naas, T., Nordmann, P., Worldwide dissemination of the bla OXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis. 16:1 (2010), 35–40 [consultado 25 Sep 2013] Disponible en: doi: http://doi.org/c3gqf5.
32. 32 Villegas, M.V., Kattan, J.N., Correa, A., Lolans, K., Guzman, A.M., Woodford, N., et al. Dissemination of Acinetobacter baumannii clones with OXA-23 carbapenemase in Colombian hospitals. Antimicrob Agents Chemother. 51 (2007), 2001–2004.
33. 33 Saavedra, S.Y., Nuñez, J.C., Pulido, I.Y., Gonzalez, E.B., Valenzuela, E.M., Reguero, M.T., et al. Characterisation of carbapenem-resistant Acinetobacter calcoaceticus-A. baumannii complex isolates in a third-level hospital in Bogotá, Colombia. Int J Antimicrob Agents. 31 (2008), 389–391.
34. 34 Evans, B.A., Amyes, S.G., OXA. β-lactamases. Clin Microbiol Rev. 27 (2014), 241–263, 10.1128/CMR 00117-13.
35. 35 Saavedra, S.Y., Cayô, R., Gales, A.C., Leal, A.L., Saavedra, C.H., Early dissemination of OXA-72-producing Acinetobacter baumannii strain in Colombia: A case report. Braz J Infect Dis. 18:6 (2014), 678–680, 10.1016/j.bjid.2014.05.017.
36. 36 Baran, G., Erbay, A., Bodur, H., Ongürü, P., Akinci, E., Balaban, N., et al. Risk factors for nosocomial imipenem–resistant Acinetobacter baumannii infections. Int J Infect Dis. 12:1 (2008), 16–21 [consultado 4 Oct 2013] Disponible en: doi: http://doi.org/bnwf4w.